You must have an order with a minimum of $150.00 to place your order, your current order total is $0.00.
Product Pillars, Peptide Education, Research Protocols
CJC-1295 + Ipamorelin: Complete Research Guide to the GH Secretagogue Stack
22
May
May
Research Use Only Notice: CJC-1295 and Ipamorelin are research peptides intended for in-vitro and animal research applications only. They are not FDA-approved as drugs or therapies. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.
CJC-1295 and Ipamorelin together form the most-studied growth hormone secretagogue stack in modern peptide research. Each compound acts on a distinct receptor — CJC-1295 mimics growth hormone-releasing hormone (GHRH), while Ipamorelin mimics ghrelin at the GHS-R receptor — producing synergistic growth hormone release that exceeds what either compound delivers alone. This complete guide from the chemistry team at OPS Peptide Science walks through how each compound works, why researchers combine them, the DAC vs. no-DAC distinction for CJC-1295, and how the stack sits in the broader peptide research catalog.
For the foundational research-workflow protocols this guide assumes, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.
What Are CJC-1295 and Ipamorelin?
CJC-1295 and Ipamorelin belong to two distinct classes of growth hormone secretagogues:
- CJC-1295 — a GHRH (growth hormone-releasing hormone) analog; mimics the body’s natural signal to the pituitary to release growth hormone
- Ipamorelin — a GHRP (growth hormone-releasing peptide); mimics ghrelin at the GHS-R receptor and triggers growth hormone release through a separate pathway
Each compound activates a different receptor on the same target cells — pituitary somatotrophs. Combining the two simultaneously activates both pathways, producing more growth hormone release than either alone. This complementary mechanism is what makes the CJC-1295 + Ipamorelin combination the most-cited GH secretagogue stack in research literature.
CJC-1295 Structure and Mechanism
CJC-1295 is a synthetic analog of GHRH (growth hormone-releasing hormone). Key features:
- 30-amino-acid peptide — based on the first 29 amino acids of natural GHRH, with a 30th residue modification
- Position 2 substitution — replaces alanine with D-alanine, preventing DPP-4 enzymatic degradation
- Two forms exist — with DAC (long-acting) and without DAC (short-acting, also called Mod GRF 1-29)
- Binds GHRH receptors on pituitary somatotrophs — same receptor as natural GHRH
The DAC (Drug Affinity Complex) modification is what differentiates the two CJC-1295 forms. With DAC, the peptide includes a maleimidopropionic acid linker that binds covalently to circulating serum albumin, extending the half-life from minutes to 6-8 days. Without DAC, CJC-1295 (Mod GRF 1-29) has a half-life of approximately 30 minutes — supporting pulsatile dosing protocols that mimic natural GHRH release patterns.
Ipamorelin Structure and Mechanism
Ipamorelin is a synthetic pentapeptide (5 amino acids) belonging to the growth hormone-releasing peptide (GHRP) class. Key features:
- Pentapeptide — Aib-His-D-2-Nal-D-Phe-Lys-NH2 (5 amino acids with modifications for stability)
- Molecular weight — approximately 712 Da
- Half-life — approximately 2 hours
- Binds the ghrelin receptor (GHS-R) — the same receptor activated by natural ghrelin
- Highly selective — minimal effect on cortisol and prolactin compared to older GHRPs (GHRP-2, GHRP-6, hexarelin)
The selectivity of Ipamorelin is what made it stand out among GHRPs in research. Older GHRPs produce GH release but also raise cortisol and prolactin to varying degrees — which complicates research data interpretation. Ipamorelin produces measurable GH release with minimal off-target effects, making it the preferred GHRP for clean research designs.
Why Combine CJC-1295 and Ipamorelin?
Combining a GHRH analog (CJC-1295) with a GHRP (Ipamorelin) produces a synergistic effect that exceeds either compound alone. The mechanism explains why:
- Two receptors, one target cell — CJC binds GHRH receptors while Ipamorelin binds GHS-R receptors, both on the same pituitary somatotrophs
- Different intracellular signaling pathways — GHRH-R activates cAMP signaling; GHS-R activates phospholipase C/Ca²⁺ signaling
- Convergent on GH release — both pathways end in growth hormone release, but they prime the cell through different signals
- Documented synergy in research — combined administration produces 5-7x more GH release than either alone in published animal research models
The combination also restores more of the natural pulsatile GH release pattern than either compound alone — the GHRH signal “primes” the cell while the GHRP signal “triggers” release, mirroring how natural GHRH and ghrelin work together physiologically. The published CJC-1295 and Ipamorelin research literature on PubMed documents this synergy across multiple research models.
CJC-1295 + Ipamorelin Research Applications
Growth Hormone Research
The largest body of CJC-1295 + Ipamorelin research focuses on growth hormone secretion itself — measuring acute GH pulses, peak heights, and cumulative GH exposure over dosing periods. This research provides the foundation for understanding the stack’s downstream effects.
IGF-1 Trajectory Research
Growth hormone stimulates IGF-1 production primarily in the liver. Research using CJC-1295 + Ipamorelin protocols measures IGF-1 trajectories over weeks of dosing — capturing how repeated GH stimulation builds steady-state IGF-1 elevation. This is a key endpoint for studies examining downstream metabolic and tissue effects.
Body Composition Research
Animal research models studying body composition — lean mass, fat mass, distribution — use CJC-1295 + Ipamorelin protocols because elevated IGF-1 produces measurable body composition shifts over 6-12 weeks of consistent dosing.
Sleep Research
Growth hormone is closely linked to slow-wave sleep, and research on GH-stimulating peptides extends into sleep biology endpoints. CJC-1295 + Ipamorelin research has documented effects on sleep architecture in animal models.
Bone Density Research
GH and IGF-1 are central to bone metabolism. Research models studying bone density, bone turnover markers, and broader skeletal biology have documented CJC-1295 + Ipamorelin effects across multi-month protocols.
Tissue Repair Research
GH and IGF-1 support cellular repair processes. Some research models pair CJC-1295 + Ipamorelin with tissue-injury models to study repair endpoints — though specific tissue-repair compounds like BPC-157 and TB-500 remain more cited for direct repair research.
CJC-1295 With DAC vs Without DAC
The DAC distinction is one of the most important decisions in CJC-1295 research protocol design:
| Property | CJC-1295 with DAC | CJC-1295 No DAC (Mod GRF 1-29) |
|---|---|---|
| Half-life | ~6-8 days | ~30 minutes |
| Dosing frequency | Weekly | Multiple times daily |
| GH release pattern | Continuous elevated | Pulsatile (mimics natural) |
| Receptor occupancy | Sustained | Episodic |
| Research use | Long-term effect studies | Pulsatile pattern research |
Research design considerations:
- For cumulative IGF-1 trajectory research — CJC-1295 with DAC is more practical due to weekly dosing
- For pulsatile GH biology research — Mod GRF 1-29 (no DAC) more closely matches natural GHRH pulse patterns
- Most combination research — uses no-DAC CJC-1295 paired with Ipamorelin in multiple-daily protocols to mimic natural GH release
- Long-term metabolic studies — sometimes use DAC version for simpler weekly protocols
The choice depends on what research endpoint you’re studying. Neither form is universally “better” — they serve different research questions.
Dosing in Research Models
Combination CJC-1295 + Ipamorelin dosing patterns in published research:
- Subcutaneous injection — standard route for both compounds in research models
- Pre-sleep administration — common in research protocols to align with natural GH release peaks during slow-wave sleep
- Multiple daily dosing — when using no-DAC CJC-1295, 2-3 doses per day to mimic pulsatile patterns
- Single weekly dose — when using DAC CJC-1295, simpler protocol logistics
- Cycle protocols — many research designs use 8-12 week dosing cycles with washout periods to study sustained effects
- Dose amounts — typically reported in μg/kg in animal research; specific protocols vary by species and endpoint
Research protocols should reference published methodology for the specific research model. The acute vs. cumulative effect timeline distinction is addressed in our guide on how long does it take for peptides to work.
Storage and Stability
Both compounds follow standard peptide stability profiles:
| Storage Condition | Form | Stability Window |
|---|---|---|
| -80°C | Lyophilized powder | 3-5+ years |
| -20°C | Lyophilized powder | 18-24 months |
| 2-8°C | Lyophilized powder | 6-12 months |
| 2-8°C | Reconstituted in BAC water | 21-28 days |
| Room temperature | Lyophilized powder | 2-4 weeks for transit |
For research designs combining both peptides, OPS Peptide Science offers a pre-mixed CJC-1295 + Ipamorelin blend that simplifies the workflow — both compounds reconstituted together at standardized ratios. For protocols requiring independent dose control, separate vials of each compound are also available. See our companion guide on how long do peptides last at room temperature for detailed stability information.
How to Identify Quality CJC-1295 + Ipamorelin
Both compounds are technically demanding to synthesize cleanly. Quality criteria:
- 99%+ HPLC-MS verified purity for both compounds independently if sold separately, or for the blend if pre-mixed
- Per-lot Certificate of Analysis documenting each compound’s purity and identity
- Mass spectrometry identity confirmation — CJC-1295 (~3367 Da with DAC, ~3367 Da without DAC for Mod GRF 1-29 differs slightly), Ipamorelin (~712 Da)
- Clear DAC vs no-DAC labeling — these are distinct products; mislabeling is a quality red flag
- Chain-of-custody documentation — traceable from manufacturer through fulfillment
- Properly lyophilized appearance — clean white cake at the bottom of the vial
- Research-use-only labeling — required by US regulations
At OPS Peptide Science, every CJC-1295 and Ipamorelin vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity, identity, and DAC status (where applicable) before opening the vial.
Regulatory Status
CJC-1295 and Ipamorelin occupy similar regulatory positions:
- Not FDA-approved — neither compound has completed clinical trials required for US drug approval
- WADA-prohibited in athletic competition (peptide hormones / growth factors category)
- Legal as research chemicals — sold in the US for in-vitro and animal research under research-use-only labeling
- Not DEA-scheduled — no controlled substance status
- Removed from compounding lists — recent FDA actions have restricted pharmacy compounding access for these compounds
For the complete legal framework around research peptides like CJC-1295 and Ipamorelin, see our detailed guide on are peptides illegal. According to NIH research literature, both compounds remain active pre-clinical research areas despite the regulatory restrictions on human use.
FAQ
What is CJC-1295?
CJC-1295 is a 30-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH). It binds GHRH receptors on pituitary somatotrophs and stimulates growth hormone release. Two forms exist: with DAC (6-8 day half-life) and without DAC, also called Mod GRF 1-29 (~30 minute half-life).
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide that mimics ghrelin at the GHS-R receptor, triggering growth hormone release. It is highly selective for GH release with minimal effects on cortisol and prolactin, distinguishing it from older GHRPs (GHRP-2, GHRP-6, hexarelin).
Why combine CJC-1295 and Ipamorelin?
The two compounds activate different receptors (GHRH-R and GHS-R) on the same pituitary cells. Combined administration produces synergistic growth hormone release — published research documents 5-7x more GH release than either alone in animal models. The combination also better mimics natural pulsatile GH biology.
Should I use CJC-1295 with DAC or without DAC?
Depends on the research design. With DAC supports weekly dosing for long-term IGF-1 trajectory and metabolic research. Without DAC (Mod GRF 1-29) supports multiple-daily dosing for pulsatile GH biology research. Most combination research uses no-DAC paired with Ipamorelin to mimic natural pulsatile release patterns.
Is CJC-1295 + Ipamorelin legal in the US?
Yes — both compounds are legally sold as research chemicals for in-vitro and animal research under research-use-only labeling. Neither is FDA-approved for human use, and WADA prohibits both in athletic competition. See our detailed guide on are peptides illegal for the full framework.
How long does it take to see effects from CJC-1295 + Ipamorelin in research?
Acute GH release peaks within 30-90 minutes of administration in research models. Cumulative IGF-1 elevation builds over 2-4 weeks of consistent dosing. Body composition and metabolic endpoints typically require 6-12 weeks. Specific timelines depend on the research endpoint being measured.
Where can I buy research-grade CJC-1295 + Ipamorelin?
Research-grade CJC-1295 and Ipamorelin are sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity for each compound, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and clear DAC vs no-DAC labeling. Browse the OPS Peptide Science catalog for verified research-grade CJC-1295 and Ipamorelin, including pre-mixed blends.
The CJC-1295 + Ipamorelin combination remains the gold-standard growth hormone secretagogue stack in modern peptide research. The dual-receptor mechanism produces synergistic GH release that exceeds either compound alone, supporting research across growth hormone biology, IGF-1 trajectories, body composition, sleep biology, and bone density endpoints. For researchers studying the GH axis at any level, this stack is one of the most-cited combinations in the modern catalog.
For research-grade CJC-1295 and Ipamorelin backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.
Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026
